AR039563A1 - Derivados de 4-(imidazol-5-il)-2-(4-sulfoanilino)pirimidina con actividad inhibidora de cdk - Google Patents

Derivados de 4-(imidazol-5-il)-2-(4-sulfoanilino)pirimidina con actividad inhibidora de cdk

Info

Publication number
AR039563A1
AR039563A1 ARP030100799A ARP030100799A AR039563A1 AR 039563 A1 AR039563 A1 AR 039563A1 AR P030100799 A ARP030100799 A AR P030100799A AR P030100799 A ARP030100799 A AR P030100799A AR 039563 A1 AR039563 A1 AR 039563A1
Authority
AR
Argentina
Prior art keywords
alkyl
ethyl
heterocyclyl
hydrogen
optionally substituted
Prior art date
Application number
ARP030100799A
Other languages
English (en)
Inventor
Ab Astrazeneca
Andrew Thomas
Original Assignee
Ab Astrazeneca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Astrazeneca filed Critical Ab Astrazeneca
Publication of AR039563A1 publication Critical patent/AR039563A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de 4-(imidazol-5-il)-2-(4-sulfoanilino)pirimidina y su uso como medicamentos, particularmente medicamentos para producir un efecto inhibidor del ciclo celular (anti-proliferación celular) en un animal de sangre caliente, por ejemplo un ser humano. Reivindicación 1: Un compuesto de la fórmula (2), (3), (4), (5), (6) y (7) de la estructura genérica de fórmula (1), donde: i) un compuesto de fórmula (2), donde: R1 es 2-(pirazolil-1-il)etilo, 3-(isoxazol-3-iloxi)propilo, 2-(isotiazol-3-iloxi)etilo, 2-(tiadiazol-3-iloxi)etilo, 1,3-dihidroxiprop-2-ilo, 1-metil-1-hidroximetiletilo, 1,1-dimetilpropilo, 1-metilciclopropilo, t-butilo, 2-morfolino-1,1-dimetiletilo, 2-pirrolidin-1-il-1,1-dimetiletilo, 2-metiltio-1,1-dimetiletilo, 1,3-dimetoxiprop-2-ilo, 1-metoxiprop-2-ilo, 1-hidroxiprop-2-ilo, 1-etoxiprop-2-ilo, 1-propoxiprop-2-ilo, etoxietilo o 2-metoxi-1,1-dimetiletilo; y R2 es hidrógeno; o R1 y R2 juntos forman 2,2-dimetilaziridin-1-ilo; o una sal aceptable para uso farmacéutico o un éster hidrolizable in vivo del mismo; ii) un compuesto de fórmula (3) donde: R1 es pirid-2-ilmetilo, 2-(2-metil-1,2,4-triazol-5-il)etilo, 2-pirid-2-iletilo, 2-piridazin-3-iletilo, 2-(3,5-dimetiltriazol-4-il)etilo, 2-pirid-3-iletilo, 2-metoxietilo, 3-(5-metilpirazol-4-il)propilo, 2-trifluorometilpirid-5-ilmetilo, 2-piridazin-4-iletilo, 1,1-dimetilprop-2-inilo, 2-etoxietilo, 2-fenoxietilo, 2-(4-metoxifenoxi)etilo, 2-(2-metoxifenoxi)etilo, 2-(viniloxi)etilo, 2-(isopropoxi)etilo y 2-(propoxi)etilo; y R2 es hidrógeno o ciano; o una sal aceptable para uso farmacéutico o un éster hidrolizable in vivo del mismo; con la salvedad de que cuando R1 es 2-metoxietilo, R2 es ciano; iii) un compuesto de fórmula (4), donde: R1 es hidrógeno, heterociclilo, alquilo C1-6 o alcoxi C1-6alquilo C1-6; donde R1 puede ser opcionalmente substituido sobre carbono por uno o más hidroxi, carboxi, alcoxi C1-6, alcoxicarbonilo C1-6, N,N-(alquil C1-6)2amino, heterociclilo, cicloalquilo C3-6 y alcoxi C1-6alcoxi C1-6; y donde si un heterociclilo contiene una porción -NH-, ese nitrógeno puede ser opcionalmente substituido por alquilo C1-6 o bencilo; R2 es hidrógeno, halo o ciano; o una sal aceptable para uso farmacéutico o un éster hidrolizable in vivo del mismo ; con la salvedad de que cuando R1 es 2-metoxietilo, ciclopropilmetilo o pirid-2-ilmetilo, R2 no es hidrógeno; iv) un compuesto de fórmula (5), donde: R1 es hidrógeno, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-6, cicloalquil C3-6alquilo C1-3, un heterociclilo o heterociclilalquilo C1-3; donde R1 puede ser opcionalmente substituido sobre carbono por uno o más metilo, etilo, metoxi, etoxi, propoxi, trifluorometilo, trifluorometoxi, 2,2,2-trifluoroetoxi o ciclopropilmetoxi; y donde si dicho heterociclilo contiene una porción -NH- ese nitrógeno puede ser opcionalmente substituido por uno o más metilo, etilo, acetilo, 2,2,2-trifluoroetilo o metoxietilo; R2 es hidrógeno, halo o ciano; R3 es alquilo C2-6; o una sal aceptable para uso farmacéutico o un éster hidrolizable in vivo del mismo; v) un compuesto de fórmula (6), donde: R1 es hidrógeno, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-3, un heterociclilo o heterociclilalquilo C1-3; donde R1 puede ser opcionalmente substituido sobre carbono por uno o más metilo, etilo, metoxi, etoxi, propoxi, trifluorometilo, trifluorometoxi, 2,2,2-trifluoroetoxi o ciclopropilmetoxi; y donde si dicho heterociclilo contiene una porción -NH- ese nitrógeno puede ser opcionalmente substituido por uno o más metilo, etilo, acetilo, 2,2,2-trifluoroetilo o metoxietilo; R2 es halo, ciano, alquilo C1-3 o alcoxi C1-3; p es 1-2; donde los valores de R2 pueden ser iguales o diferentes; R3 es hidrógeno, halo o ciano; R4 es alquilo C1-4; R5 es alquilo C1-6 o alquenilo C2-6; donde R5 puede ser opcionalmente substituido sobre carbono por uno o más metoxi, etoxi, propoxi, trifluorometilo, trifluorometoxi, 2,2, 2-trifluoroetoxi o ciclopropilmetoxi; o una sal aceptable para uso farmacéutico o un éster hidrolizable in vivo del mismo; con la salvedad que dicho compuesto no es 4-(1,2-dimetilimidazol-5-il)-2-[2-metoxi-4-(N-metilsulfamoil)-5-metilanilino]pirimidina; vi) un compuesto de fórmula (7), donde: R1 es alquilo C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-6, cicloalquil C3-6alquilo C1-3, un heterociclilo o heterociclilalquilo C1-3; donde R1 puede ser opcionalmente substituido sobre carbono por uno o más metilo, etilo, metoxi, etoxi, propoxi, trifluorometilo, trifluorometoxi, dimetilamino, 2,2,2-trifluoroetoxi, fenil o ciclopropilmetoxi; y donde si dicho heterociclilo contiene una porción -NH- es nitrógeno puede ser opcionalmente substituido por uno o más metilo, etilo, acetilo, 2,2,2-trifluoroetilo o metoxietilo; R2 es halo, ciano, alquilo C1-3 o alcoxi C1-3; p es 0-2; donde los valores de R2 pueden ser iguales o diferentes; R3 es hidrógeno, halo o ciano; R4 es alquilo C2-6; R5 es alquilo C1-6 o alquenilo C2-6; donde R5 puede ser opcionalmente substituido sobre carbono por uno o más metoxi, etoxi, propoxi, trifluorometil, trifluorometoxi, 2,2,2-trifluoroetoxi o ciclopropilmetoxi; o una sal aceptable para uso farmacéutico o un éster hidrolizable in vivo del mismo; vii) un compuesto de fórmula (8), donde: R1 es alquilo C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-6, cicloalquil C3-6alquilo C1-3, un heterociclilo o heterociclilalquilo C1-3; donde R1 puede ser opcionalmente substituido sobre carbono por uno o más metilo, etilo, metoxi, etoxi, propoxi, trifluorometilo, trifluorometoxi, dimetilamino, 2,2,2-trifluoroetoxi, fenilo o ciclopropilmetoxi; y donde si dicho heterociclilo contiene una porción -NH- ese nitrógeno puede ser opcionalmente substituido por uno o más metilo, etilo, acetilo, 2,2,2-trifluoroetilo o metoxietilo; R2 es halo, ciano, alquilo C1-3 o alcoxi C1-3; p es 0-2; donde los valores de R2 pueden ser iguales o diferentes; R3 es hidrógeno, halo o ciano; R4 es n-propilo o alquilo C4-6; o una sal aceptable para uso farmacéutico o un éster hidrolizable in vivo del mismo.
ARP030100799A 2002-03-09 2003-03-07 Derivados de 4-(imidazol-5-il)-2-(4-sulfoanilino)pirimidina con actividad inhibidora de cdk AR039563A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0205693.5A GB0205693D0 (en) 2002-03-09 2002-03-09 Chemical compounds

Publications (1)

Publication Number Publication Date
AR039563A1 true AR039563A1 (es) 2005-02-23

Family

ID=9932723

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100799A AR039563A1 (es) 2002-03-09 2003-03-07 Derivados de 4-(imidazol-5-il)-2-(4-sulfoanilino)pirimidina con actividad inhibidora de cdk

Country Status (21)

Country Link
US (1) US7465728B2 (es)
EP (1) EP1487823A1 (es)
JP (2) JP3569524B1 (es)
KR (1) KR20040091114A (es)
CN (1) CN1649863A (es)
AR (1) AR039563A1 (es)
AU (1) AU2003214394A1 (es)
BR (1) BR0308212A (es)
CA (1) CA2478701A1 (es)
GB (1) GB0205693D0 (es)
IL (1) IL163910A0 (es)
IS (1) IS7439A (es)
MX (1) MXPA04008807A (es)
NO (1) NO20043851L (es)
PL (1) PL372703A1 (es)
RU (1) RU2004130440A (es)
TW (1) TW200306838A (es)
UA (1) UA78292C2 (es)
UY (1) UY27705A1 (es)
WO (1) WO2003076436A1 (es)
ZA (1) ZA200406937B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
JP2005524672A (ja) 2002-03-09 2005-08-18 アストラゼネカ アクチボラグ Cdk阻害活性を有するイミダゾリル置換ピリミジン誘導体
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
GB0504753D0 (en) * 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
KR20080033450A (ko) 2005-07-30 2008-04-16 아스트라제네카 아베 증식성 질환의 치료에 사용하기 위한 이미다졸릴-피리미딘화합물
AU2006282428A1 (en) 2005-08-23 2007-03-01 Ube Industries, Ltd. Method for producing 1-substituted-5-acylimidazole compound
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US20080214560A1 (en) * 2005-10-03 2008-09-04 Astrazeneca Ab Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease
UY29827A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
JP2009541285A (ja) 2006-06-21 2009-11-26 アストラゼネカ アクチボラグ 化学化合物
DK2046292T3 (da) * 2006-07-21 2010-06-07 Novartis Ag Formuleringer for benzimidazolylpyridylethere
JP5693951B2 (ja) * 2007-04-24 2015-04-01 アストラゼネカ エービー プロテインキナーゼの阻害剤
US8507498B2 (en) 2007-04-24 2013-08-13 Ingenium Pharmaceuticals Gmbh 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
JP5379787B2 (ja) * 2007-04-24 2013-12-25 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
US8507511B2 (en) 2007-04-24 2013-08-13 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
US8420678B2 (en) 2008-04-14 2013-04-16 Board Of Regents, The University Of Texas System Small molecule inhibitors of the pleckstrin homology domain and methods for using same
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
MX2011010732A (es) * 2009-04-15 2011-11-18 Astrazeneca Ab Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer.
EP2909176B1 (en) * 2012-10-18 2016-07-20 Bayer Pharma Aktiengesellschaft 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
WO2014093988A2 (en) 2012-12-14 2014-06-19 Phusis Therapeutics, Inc. Methods and compositions for inhibiting cnksr1
WO2016172191A1 (en) 2015-04-20 2016-10-27 Phusis Therapeutics, Inc. Compounds, compositions and methods for inhibiting cnksr1
WO2016205806A1 (en) * 2015-06-18 2016-12-22 St. Jude Children's Research Hospital Methods and compositions for the prevention and treatment of hearing loss
US11759450B2 (en) 2018-02-06 2023-09-19 The Board Of Trustees Of The University Of Illinois Substituted benzothiophene analogs as selective estrogen receptor degraders
CN110314161A (zh) * 2018-03-30 2019-10-11 潍坊医学院 化合物在制备治疗肿瘤的药物中的用途
EP4073102A4 (en) 2019-12-12 2024-05-08 Ting Therapeutics LLC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS
US11857551B1 (en) 2020-07-10 2024-01-02 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659363A (en) 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
AU3342689A (en) * 1988-03-24 1989-10-16 Igen Incorporated Luminescent chimeric proteins
US4946956A (en) 1988-09-21 1990-08-07 Uniroyal Chemical Company, Inc. Arylenediamine substituted pyrimidines
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US4983608A (en) 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
AU672790B2 (en) * 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
WO1994007890A1 (en) 1992-10-05 1994-04-14 Ube Industries, Ltd. Pyrimidine compound
US6077822A (en) * 1993-09-14 2000-06-20 Dumex-Alpharma A/S Drug salts
EP0672041B1 (en) 1993-10-01 2001-11-14 Novartis AG Pharmacologically active pyridine derivatives and processes for the preparation thereof
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
AU693475B2 (en) 1993-10-01 1998-07-02 Novartis Ag Pyrimidineamine derivatives and processes for the preparation thereof
US5705502A (en) 1993-10-01 1998-01-06 Novartis Corporation Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
ES2201112T3 (es) 1994-08-13 2004-03-16 Yuhan Corporation Nuevos derivados de pirimidina y procedimientos para su preparacion.
DK0813525T3 (da) 1995-03-10 2004-02-16 Berlex Lab Benzamidinderivater, deres fremstilling og anvendelse som antikoagulanter
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US5658903A (en) 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US6852690B1 (en) * 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
WO1997040017A2 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
DE19616486C5 (de) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
EP0906307B1 (en) 1996-06-10 2005-04-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
WO1998016230A1 (en) 1996-10-17 1998-04-23 Smithkline Beecham Corporation Methods for reversibly inhibiting myelopoiesis in mammalian tissue
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
US7091183B1 (en) * 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
ATE391719T1 (de) 1997-02-05 2008-04-15 Warner Lambert Co Pyrido (2,3-d) pyrimidine und 4-amino-primidine als inhibitoren der zellulären proliferation
US5846937A (en) * 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
DE19710435A1 (de) 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
US5998204A (en) * 1997-03-14 1999-12-07 The Regents Of The University Of California Fluorescent protein sensors for detection of analytes
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
CA2293436C (en) 1997-06-12 2010-10-26 Rhone-Poulenc Rorer Limited Imidazolyl-cyclic acetals as tnf inhibitors
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
JP2001519345A (ja) 1997-10-02 2001-10-23 メルク エンド カムパニー インコーポレーテッド プレニルタンパク質トランスフェラーゼの阻害剤
EP1021173A1 (en) 1997-10-10 2000-07-26 Imperial College Innovations Limited Use of csaid?tm compounds for the management of uterine contractions
AU1507199A (en) 1997-12-15 1999-07-05 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives
AR017219A1 (es) 1997-12-19 2001-08-22 Smithkline Beecham Corp Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento
NZ506417A (en) 1998-02-17 2003-05-30 Tularik Inc Anti-viral pyrimidine derivatives
SI0945443T1 (en) 1998-03-27 2003-08-31 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidine derivatives
GB9806739D0 (en) 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
ES2270612T3 (es) 1998-08-29 2007-04-01 Astrazeneca Ab Compuestos de pirimidina.
ES2274634T3 (es) 1998-08-29 2007-05-16 Astrazeneca Ab Compuestos de pirimidina.
PL346700A1 (en) 1998-09-18 2002-02-25 Basf Ag Pyrrolopyrimidines as protein kinase inhibitors
SK3852001A3 (en) 1998-09-18 2003-03-04 Basf Ag 4-Aminopyrrolopyrimidines as kinase inhibitors
DE69926007T2 (de) * 1998-10-07 2005-12-29 Medical College Of Georgia Research Institute, Inc. Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon
US6531477B1 (en) 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
JP2002528499A (ja) 1998-10-29 2002-09-03 ブリストル−マイヤーズ スクイブ カンパニー Impdh酵素のインヒビターであるアミノ核誘導化合物
WO2000026209A1 (en) 1998-11-03 2000-05-11 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
IL144675A0 (en) 1999-02-01 2002-05-23 Cv Therapeutics Inc PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-α
US7745216B2 (en) * 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6627633B2 (en) 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
WO2000058360A2 (en) * 1999-03-29 2000-10-05 Uutech Limited Analogs of gastric inhibitory peptide and their use for treatment of diabetes
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
WO2001030778A1 (en) 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use
PL355912A1 (en) 1999-11-22 2004-05-31 Smithkline Beecham Plc. Novel compounds
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
WO2001047921A1 (en) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
CA2400447C (en) 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US20030157107A1 (en) * 2000-05-16 2003-08-21 Kazumasa Miyawaki Agents for preventing or ameliorating insulin resistance and/or obesity
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
WO2002010195A2 (en) * 2000-08-02 2002-02-07 Theratechnologies Inc. Modified peptides with increased potency
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
WO2002066480A2 (en) 2001-02-20 2002-08-29 Astrazeneca Ab 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
SE0100569D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab New compounds
AU2002308748A1 (en) 2001-05-16 2002-11-25 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
JP4291135B2 (ja) 2001-05-29 2009-07-08 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Cdk阻害性ピリミジン、それらの製造および薬剤としての使用
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
AU2002317599B2 (en) * 2001-07-31 2008-04-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
WO2003011837A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
GB0123589D0 (en) 2001-10-01 2001-11-21 Syngenta Participations Ag Organic compounds
DE60211539T2 (de) 2001-10-05 2006-09-21 Smithkline Beecham Corp. Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
BR0213792A (pt) 2001-11-01 2004-12-07 Janssen Pharmaceutica Nv Heteroaril aminas como inibidores de glicogênio sintase cinase 3beta (inibidores de gsk3)
BR0213899A (pt) 2001-11-07 2004-08-31 Hoffmann La Roche Aminopirimidinas e aminopiridinas
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
JP2005524672A (ja) 2002-03-09 2005-08-18 アストラゼネカ アクチボラグ Cdk阻害活性を有するイミダゾリル置換ピリミジン誘導体
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US20030232761A1 (en) * 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
WO2003105760A2 (en) * 2002-06-15 2003-12-24 Enteromed, Inc. Prevention and treatment of nonalcoholic fatty liver disease (nafld) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (gip)
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
GB0226582D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Anti-viral compounds
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
US7276502B2 (en) 2003-03-25 2007-10-02 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
WO2004087698A2 (en) 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
CN102174102A (zh) * 2003-05-15 2011-09-07 塔夫茨大学信托人 肽和多肽药物的稳定类似物
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
JP2008514571A (ja) 2004-09-29 2008-05-08 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 細胞周期−キナーゼまたはレセプター−チロシン−キナーゼインヒビターとしての置換2−置換アニリノピリミジン類、それらの製造および薬剤としての使用
RU2007114080A (ru) 2004-10-13 2008-11-27 Вайет (Us) N-бензилсульфонил-замещенные аналоги анилинопиримидина

Also Published As

Publication number Publication date
PL372703A1 (en) 2005-07-25
NO20043851L (no) 2004-09-14
BR0308212A (pt) 2004-12-21
GB0205693D0 (en) 2002-04-24
JP2005519135A (ja) 2005-06-30
WO2003076436A1 (en) 2003-09-18
RU2004130440A (ru) 2005-05-10
CN1649863A (zh) 2005-08-03
TW200306838A (en) 2003-12-01
UY27705A1 (es) 2003-10-31
MXPA04008807A (es) 2004-11-26
JP2004256550A (ja) 2004-09-16
ZA200406937B (en) 2006-02-22
US20050131000A1 (en) 2005-06-16
IL163910A0 (en) 2005-12-18
KR20040091114A (ko) 2004-10-27
US7465728B2 (en) 2008-12-16
EP1487823A1 (en) 2004-12-22
UA78292C2 (en) 2007-03-15
IS7439A (is) 2004-09-07
AU2003214394A1 (en) 2003-09-22
JP3569524B1 (ja) 2004-09-22
CA2478701A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
AR039563A1 (es) Derivados de 4-(imidazol-5-il)-2-(4-sulfoanilino)pirimidina con actividad inhibidora de cdk
RU2401267C2 (ru) Замещенные производные бензохинолизина
EA200800727A1 (ru) Введение ингибиторов дипептидилпептидазы
AR104566A2 (es) Forma cristalina de la sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo
CO6251260A2 (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
WO2009010789A3 (en) Pyrimidine derivatives 934
NO20022683D0 (no) Ureaforbindelser med muskarinisk reseptor-antagonistaktivitet
DE50302975D1 (de) Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel
BRPI0414084A (pt) composto, mistura, e, composição
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
PE20091243A1 (es) Compuesto heterociclico fusionado
DE502005006204D1 (de) 8- ä3-amino-piperidin-1-ylü-xanthine, deren herstellung und deren verwendung als arzneimittel
SMT201300098B (it) Forme solide di N-(4-(7-azabiciclo[2.2.1]eptan-7-il)-2-(trifluorometil)fenil-4-osso-5-trifluorometil)-1,4-diidrochinolina-3-carbossammide
DE60113080D1 (de) 4-amino-5-cyano-2-anilino-pyrimidin-derivate zur verwendung als inhibitoren von zellzyklus-kinasen
TN2009000160A1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoides
JP2006188542A5 (es)
PE20130239A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
HUP0301573A2 (hu) Szubsztituált arilpirazinok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CO6311102A2 (es) Derivados carboxílicos y alcoxi de 4-sustituido-2-[4-({(5-metil-1h-pirrol -2-il) carbonil} amino)- piperidin sustituido -1-il]-1,3-tiazol como inhibidores de dna girasa y/o topoisomerasa iv y composiciones farmacéuticas de los mismos
PE20090216A1 (es) Compuestos triazolil aminopirimidina
AR039399A1 (es) Compuestos quimicos con actividad doble, procedimientos para su preparacion y composiciones farmaceuticas
AR053169A1 (es) Metabolitos de n-2 (cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil) -2-metil -4-pi rimidinil] amino]-5-tiazol carboxamidas
PE20061373A1 (es) Composicion farmaceutica que contiene 'n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamida
WO2006123165A3 (en) Pyrimidine derivatives as hsp90 inhibitors
NO883487L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal